+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the use of avapritinib, an oral drug targeting a specific KIT mutation, for people with Indolent Systemic Mastocytosis ISM in Germany. This observational study aims to understand how avapritinib works in real-world settings and to fill gaps in knowledge about the natural course and management of ISM, especially in patients whose symptoms are not well controlled by existing treatments. Participants will receive avapritinib as part of their regular treatment plan with their healthcare provider, following approved guidelines. The study will observe participants for up to 24 months while they take the medication as prescribed in routine care. Researchers will monitor changes in symptoms and quality of life using specific questionnaires and scores over time. During the study, participants will have assessments at the start and at various points up to 24 months, including questionnaires on quality of life and symptom control, blood tests measuring certain markers, and records of medical history and treatments. The main measure is the change in a quality of life questionnaire score at 6 months. Other outcomes include symptom scores, medication changes, hospital visits, and safety events related to ISM and avapritinib use.

Age: 18Years +All Genders
12 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
C

Actively Recruiting

Researchers are evaluating the combination of Surovatamig AZD0486 and rituximab for treating participants with previously untreated follicular lymphoma. This global, randomized, open-label Phase III study aims to compare the efficacy, safety, and added benefit of this combination versus three standard immunochemotherapy regimens chosen by the investigator. The study includes a safety run-in phase to determine the recommended dose followed by the main Phase III comparison. The study has two parts first, a safety run-in to compare different dose levels of Surovatamig combined with rituximab to establish the recommended Phase III dose RP3D. Then, the Phase III part, which compares three treatment arms two with different Surovatamig plus rituximab schedules and one with investigators choice of standard chemoimmunotherapy regimens R-CVP, R-CHOP, or B-R followed by rituximab maintenance. Participants are randomly assigned to one of these arms. During the study, participants undergo safety monitoring, including tracking of adverse events and treatment tolerability, for up to 10 years. Researchers assess treatment response, progression, and survival outcomes over this period. Participants receive regular evaluations of disease status, organ function, and overall health. The study aims to measure safety, the best dose, and whether Surovatamig plus rituximab is superior to standard treatments in this patient group.

Age: 18Years - 130YearsAll GendersPhase 3
244 locations
N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two fixed-duration drug combinations for adults with previously untreated chronic lymphocytic leukemia CLL. This Phase 3 study compares sonrotoclax plus zanubrutinib against venetoclax plus acalabrutinib to see which therapy better controls the disease. The trial is sponsored by BeOne Medicines and focuses on treatment outcomes in this patient group. Participants receive either sonrotoclax and zanubrutinib or venetoclax and acalabrutinib, both given orally for a set period. After completing the drug regimen, participants enter an observation phase to monitor their health and disease status. The study uses a randomized, parallel design without masking, meaning participants are assigned to one of two treatment groups openly. During the trial, participants undergo regular assessments including imaging to measure disease size, evaluations of bone marrow and organ function, and monitoring for side effects. The primary outcomes include progression-free survival monitored for up to about 70 months and rates of undetectable minimal residual disease measured up to approximately 16 months. Secondary outcomes cover response rates, overall survival, adverse events, and quality of life scores. The total study duration extends to late 2031, allowing long-term follow-up and safety evaluation.

Age: 18Years +All GendersPhase 3
115 locations
P

Actively Recruiting

Researchers are evaluating disease-free survival in patients with resected pancreatic ductal adenocarcinoma PDAC through a multicenter, open-label phase III trial. The study compares chemotherapy allocation based on a transcriptomic treatment specific stratification signature TSS with the standard clinical criteria. The main goal is to see if using the TSS to guide treatment choice improves patient outcomes compared to current standard methods. Participants receive adjuvant chemotherapy with either mFOLFIRINOX a combination of 5-FU, folinic acid, irinotecan, and oxaliplatin or GemCap gemcitabine and capecitabine. In the test arm, treatment is assigned according to the individual transcriptomic signature, while in the control arm, treatment follows standard clinical criteria. Chemotherapy cycles last about 24 weeks, with drugs given in specific doses and schedules, including infusions every 14 days for mFOLFIRINOX and cycles of 28 days repeated six times for GemCap. During the study, participants are closely monitored for disease-free survival up to 76 months. Assessments include overall survival, metastasis-free survival, quality of life using the EORTC QLQ-C-30 questionnaire, and safety evaluations of adverse events and toxicities. The study also includes optional translational research with collection of tumor specimens and blood samples to identify biomarkers predicting chemotherapy response or relapse, development of patient-derived organoids, and a longitudinal blood biobank for analyzing circulating biomarkers. The total study duration extends through primary completion in April 2033 and final completion in September 2034.

Age: 18Years - 79YearsAll GendersPhase 3
33 locations
S

Actively Recruiting

Researchers are evaluating EIK1005, a selective Werner helicase inhibitor, alone and in combination with pembrolizumab in people with advanced solid tumors, including those with Microsatellite Instability High MSI-H or Mismatch Repair Deficient dMMR tumors. This Phase 12 study aims to find the safest and most effective dose of EIK1005 and assess its safety, how the body processes it, and its initial effects. The study has two parts Part 1 includes dose escalation with EIK1005 alone Part 1A or combined with pembrolizumab Part 1B. Part 2 involves dose optimization where participants with MSI-H or dMMR tumors are randomly assigned to receive one of two selected doses of EIK1005 monotherapy. Participants without other treatment options may receive EIK1005 alone, while those with MSI-H or dMMR tumors may receive combination therapy or monotherapy depending on their group. Participants will be monitored regularly during treatment to assess side effects and how well the drugs are tolerated. Researchers will conduct scans, lab tests, and clinical evaluations to measure tumor response and control, treatment safety, and drug levels in the body. Follow-up will continue for up to two years to track outcomes such as disease progression and response duration. The total study period extends up to March 2029.

Age: 18Years +All GendersPhase 1Phase 2
45 locations
M

Actively Recruiting

Researchers are evaluating the addition of letrozole, an aromatase inhibitor, to the standard maintenance therapy in women diagnosed with estrogen-receptor ER positive epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer. This study focuses on both low and high grade serous or endometrioid ovarian cancers at FIGO Stage II-IV, whose cancer has not progressed after primary surgery and platinum-based chemotherapy. The main goal is to determine if letrozole can increase progression-free survival compared to the current standard maintenance treatment with placebo. Participants are randomly assigned to receive either letrozole 2.5 mg daily or a placebo tablet once daily for up to five years or until toxicity symptoms or disease progression occur. This randomized, double-blinded, multicenter phase III trial involves 540 eligible women who will be monitored throughout the treatment period. The study also includes a sub-study focusing on low grade ovarian cancer LOGOS. Treatment adherence and tolerability will be assessed during regular visits. Participants will undergo health assessments including blood tests, physical and gynecological exams, and possibly imaging during routine follow-ups every 12 weeks for the first two years, then every 24 weeks for three additional years. Quality of life will be evaluated using specific questionnaires, and participants will wear an activity tracker for one week before visits. Researchers will measure progression-free survival as the primary outcome and also evaluate overall survival, time to next treatment, and quality-adjusted survival. Follow-up data will be collected for up to 12 years, including up to seven years after treatment ends to monitor long-term outcomes.

Age: 18Years +FEMALEPhase 3
53 locations
N

Actively Recruiting

Researchers are gathering real-world data from patients in Germany with non-squamous metastatic non-small cell lung cancer NSQ mNSCLC, including large cell neuroendocrine carcinoma when considered similar to NSCLC. The study focuses on patients beginning their first-line treatment with a combination of tremelimumab, durvalumab, and platinum-based chemotherapy TDC as approved. It aims to understand treatment effectiveness based on specific genetic mutations like KRAS, STK11, KEAP1, TP53, and markers such as TTF-1 and PD-L1 to help guide personalized treatment strategies for high-need patient subgroups. Participants are observed without receiving additional interventions beyond their planned standard treatment with TDC. The study collects data according to routine clinical practice during the patients treatment course. Biomarker testing including molecular sequencing and expression analyses is performed as per institutional standards to classify patient subgroups. During the study, participants survival and treatment responses are tracked for up to 24 months, with key outcomes including real-world overall survival rates at two years, progression-free survival, and safety through adverse event collection. Data are gathered at multiple time points up to two years to evaluate outcomes in the overall population and in subgroups defined by genetic mutations. Participants provide informed consent and must meet specific eligibility criteria to join.

Age: 18Years - 120YearsAll Genders
30 locations
P

Actively Recruiting

Researchers are investigating the effects of additional chemotherapy treatment after surgery or ablation in patients with metastatic colorectal cancer whose tumor lesions have been definitively treated. This phase III, open-label, randomized, controlled trial aims to compare the effectiveness, quality of life, and safety of mFOLFOXIRImFOLFOX-6 chemotherapy against active follow-up without additional chemotherapy. The study also includes a translational research component to analyze tumor biopsies and blood samples for disease relapse markers. Patients are assigned randomly in a 21 ratio to receive either active chemotherapy mFOLFOXIRI, mFOLFOX6, FOLFIRI, or CAPOX for up to six months or structured follow-up without chemotherapy. Chemotherapy regimens involve intravenous infusions and oral medications administered in cycles every two or three weeks, with a maximum of 12 cycles for most treatments. After treatment or follow-up, participants continue with structured monitoring for up to five years. Participants undergo re-assessments every three months during the first two years, including CT or MRI scans of the thorax and abdomen, blood tests, and quality of life evaluations to detect disease relapse. After two years without relapse, follow-up intervals extend to every six months. The primary outcome measured is progression-free survival at 24 months, with secondary outcomes including overall survival, lesion control, adverse events, and quality of life monitored for up to five years following randomization.

Age: 18Years +All GendersPhase 3
79 locations

1-10 of 12

1